Mariko Harada-Shiba received her MD from Shiga University of Medical Science in 1984 and PhD in 1988. She then held a Post-Doctoral and Research Associate position in the Department of Etiology and Pathophysiology (Dr. Akira Yamamoto’s lab) in National Cardiovascular Center and studied LDL apheresis therapy in homozygous and heterozygous FH patients. In 1996, she joined the Department of Biochemistry (Dr. Richard Hanson’s lab) in Case Western Reserve University in USA. She has been devoted to FH studies
involving analysis of CAD risk, establishment of Japanese guideline and development of new therapeutic approach using antisense drugs.
Now, she is the Director of the Department of Molecular Innovation in Lipidology in National Cerebral and Cardiovascular Center.
She is a Council member of Science Council of Japan, a Board Director of Japan Apheresis Society and a Council Member of Japan Atherosclerosis Society.